Abstract 4561
Background
Discrepancies in perception of adverse events between patients and physicians may influence the follow up services of cancer patients. With patient ratings as the gold standard, physicians more often underrate the symptom severities. In breast cancer (BC) populations, studies of interrater agreement are deficient. We evaluated the agreement between BC patients and their oncologists on the rating of symptoms and functioning in a clinical follow-up study at Trondheim University Hospital.
Methods
At five clinical controls during the first year after primary treatment BC patients (n = 250) and their oncologist (n = 14) reported symptoms and functions by completing the EORTC QLQ-C30/QLQ-BR23 and CTCAE questionnaires, respectively. Fatigue, hot flushes, breast pain, arm pain, emotional and physical functioning were comparable and scored on a four point Likert scale: not at all, mild, moderate and severe. The degree of agreement was evaluated by the Kappa(κ) coefficient. The McNemar-Bowker Test was used to test for association between raters and rating outcome.
Results
Four symptoms and two functions were assessed five times. Of 35 assessments, poor agreement (κ < 0.20) was identified on 24 assessments, fair agreement (0.21< κ > 0.40) on 10 assessments and moderate agreement (κ = 0.41) on one assessment (physical function). Overall, the oncologists rated the severity of all symptoms and the functions significantly lower than the patients (p < 0.01). The agreement decreased with increasing symptom severity and function impairment.
Conclusions
Discrepancies in reporting symptom severity between patients and oncologists might be due to high subjectiveness of symptoms and different understanding of the construct being measured. Personal characteristics of both raters, the context of the clinical controls and the nature of the relationship between patients and physicians may also contribute to discrepancies. Our results emphasize the importance of collecting patient reported data during follow up after BC treatment as it may improve diagnosis and treatment of adverse effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NTNU, Department of Circulation and Medical Imaging, the authors.
Funding
Norwegian University of Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract